Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis Abstract Purpose: The purpose of this study was to compare the safety and efficacy of DPP-4 inhibitors versus sulfonylurea as adjunctive second-line therapy in patients with type 2 diabetes mellitus, inadequately controlled with metformin mono-therapy.
Metformin is the most commonly prescribed first-line oral hyperglycemic agent (OHA) for patients with type 2 diabetes. It produces a reduction in HbA1c of between 1% and 2% in patients with a low frequency of hypoglycaemia [1, 2]; however, in patients with type 2 diabeties, due to progressive failure of insulin secretion over time, metformin fails to maintain glycemic control and the addition of second-line medications are required to achieve plasma glycemic levels consistent with current guidelines (e.g., haemoglobin A1c (HbA1c) < 7 or <6.5%) [3] . Sulfonylureas (SU) are the most common second-line therapeutic drugs and can help patients achieve or maintain glycaemic control when added to metformin [4, 5] but can result in hypoglycaemia [6] and weight gain [7] . Over the last decade, dipeptidyl peptidase 4 (DPP-4) inhibitors have been introduced worldwide as an alternative to SU as second-line therapy in patients in whom metformin mono-therapy is no longer sufficient [8] .
In the present study, we have evaluated the safety and efficacy of DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin) as alternatives to sulfonylurea for second-line therapy in conjunction with metformin. Diabetes micro-and macro-vascular complications (cardiovascular events; CVE) were the primary efficacy outcomes to be evaluated and HbA1c is a secondary (surrogate) outcome. Hypoglycemia was the primary adverse (safety) outcome assessed as this would be the most frequent serious adverse effect associated with oral hypoglycemic therapies [8] .
Materials and Methods

Systematic search of literature
This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines [9] . A medical librarian developed the search strategy, in collaboration with the primary investigator (NF). Search filters for the concepts "diabetes mellitus type 2, sulfonylurea and DPP-4 inhibitors" were constructed using a combination of database terms and text words. Database terms were adapted for each electronic database searched. The OVID interface was applied to perform electronic searches in MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations (n=269) and EMBASE (n=2753) as well as PubMed (n=438) and the Cochrane Central Register of Controlled Trials (n=101) searching for randomized controlled trials (RCTs) published in any language from 1980 to June 2015 (Appendix I).
The research question and study eligibility criteria for this systematic review are based upon the following PICOS descriptions [10]:
• Population: all adults with type 2 diabetes mellitus requiring an OHA to be added to metformin because of inadequate glycemic control (HbA1c > 6.5%, fasting plasma glucose > 7 mmol/L or 2-hour postprandial glucose > 10 mmol/L);
• Intervention: any DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin or vildagliptin);
• Comparator: Sulfonylurea compounds (gliclazide, glipizide, glyburide and glimepiride) in the treatment of type 2 diabetes (as second-line adjunctive therapy);
• Patient important outcome(s): Cardiovascular events (refer to any incidents that may cause damage to the heart muscle; e.g., high blood pressure, arterial stiffness, etc.), HbA1c (%) (mean change from baseline), body weight (kg), body mass index (BMI) (kg/m 2 ) and severe hypoglycemic event rate (confirmed hypoglycaemia was defined as a finger-stick glucose value ≤2.8 mmol/dl with associated symptoms); and,
• Study type(s): randomized controlled trials (RCTs) on humans, with at least 12 weeks of follow-up duration and published in any language. Studies were excluded if they were (1) post hoc analyses of previous RCTs, (2) unpublished trials, abstracts or conference proceedings, (3) trials with no active comparator or (4) trials that do not measure any of the primary clinical outcomes.
Study selection, data abstraction and quality assessment
Two review authors (NF and SM) independently selected studies for inclusion from the list of 3,081 pertinent papers (after deleting duplicates). From the titles and abstracts of all studies identified by the electronic search, those that clearly did not satisfy inclusion criteria were excluded. Full copies of the remaining studies were obtained and reviewed to identify those suitable for inclusion and data abstraction. Disagreements or uncertainty were resolved by consensus and if they persisted, were arbitrated through discussion with a third review author. Two review authors (NF and SM) also independently assessed risk of bias for included RCTs using the Cochrane Collaboration's Risk of Bias tool and abstracted data using a study-specific data extraction form. Disagreements or uncertainty were resolved by consensus. The primary author (NF) entered the final data into the Cochrane Collaboration's Review Manager (RevMan®) Analysis Version 5.3 statistical software for meta-analysis. Data from RevMan 5.3 was then exported into GRADEprofiler® (GRADE Working Group) to assess the quality of evidence per outcome and ultimately to create the summary of findings table and evidence profile. No formal assessment of publication bias could be performed as there were too few studies to generate a meaningful funnel plot per outcome.
Statistical Analysis
To compare the treatment effects between the two treatment groups (SU vs. DPP-4 inhibitors), a meta-analysis was planned where identified studies were sufficiently homogeneous in terms of participants, interventions and outcomes. In the case of continuous outcomes (i.e., HbA1c % and body weight), pooled results were summarized using a mean difference and a 95% confidence interval (CI). In the case of dichotomous outcomes (hypoglycemic events) pooled results were summarized using a relative risk (RR) and a 95% CI and the Mantel-Haenszel method was used to pool effect estimates. The meta-analysis was carried out using a random-effects model that awards relatively more weight to smaller studies compared to a fixed-effects meta-analysis. Regarding the assessment of heterogeneity and the a priori hypotheses for sub-group analysis, following the GRADE guidelines we assessed the source of heterogeneity considering patient baseline HbA1c%, intervention and differences in follow-up duration. Heterogeneity also was evaluated statistically using the I 2 and the degree of overlap of CIs for the results of individual studies. Sensitivity analysis was performed between low and high risk of bias, and with or without biased studies.
Results
Study selection. The database search results are summarized in Figure 1 . Among the 34 full-text articles that were assessed for eligibility, 10 [11-20] fulfilled all the inclusion criteria and none of the exclusion criteria. The reasons for excluding 24 potential RCTs [8, were as follows: more than one drug being added to metformin mono-therapy at one time; non-randomization; less than 12 weeks of follow-up; not a full manuscript; post hoc analysis of a previous trial; and, duplicate studies (Appendix II).
Study and patient characteristics. Table 1 summarizes the characteristics of the 10 RCTs: 10,139, 9,187 and 10,616 participants were included for evaluating the HbA1c% change from baseline, body weight and the hypoglycemia event rate, respectively.
Methodological quality and risk of bias. As shown in Table  2 , the studies were found to be of "low risk of bias". Incomplete outcome data (missing data) was quite high in four studies [15, 16, 18, 19] and there were concerns about risk of bias in these four studies [14] [15] [16] 19 ]; thus, the ultimate quality of evidence per outcome according to GRADE guidelines [44-46] was reported as "moderate" (Appendix III, summary of finding tables).
Efficacy assessment
Cardiovascular events (CVE): As per efficacy primary outcome, no studies measured CVE. One RCT [17] evaluated efficacy of DPP-4 inhibitors vs. SUs plus metformin on related CV outcomes in which 16 subjects were tested for arterial stiffness and 34 participants were examined for systolic and diastolic blood pressure (surrogates). After three months follow-up no changes were observed from baseline regarding arterial stiffness (MD=-1.43, 95% CI -6.54-3.68, P=0.58) and nonsignificant decreases in systolic (MD=-0.9, 95% CI -4.97-3.17, P=0.66) and diastolic blood pressure (MD=0.54, 95% CI -2.98-4.06, P=0.76) occurred during the study period (Appendix IV).
HbA1c% difference from baseline: As illustrated in Figure 2 , the results of the meta-analysis showed a non-significant difference between the test and the control groups (MD=0.06, 95% CI -0.00-0.13, P=0.07) from the 10 studies evaluating HbA1c% (difference from baseline) in 10,139 subjects. Following a sensitivity analysis that was performed to test the robustness of the results comparing high risk of bias (for missing data >20%) studies [15, 16, 18, 19 ] to low risk, the results changed to a significant difference in favor of SUs and heterogeneity (I 2 ) decreased from 73% to less than 50%. No change was observed in the results following a sensitivity analysis of assessing studies with low vs. high risk of bias.
Safety assessment: Figure 3 shows the results of the meta-analysis of eight RCTs [11, 13, 15-20] involving 10,616 diabetic patients, with at least one hypoglycemic event during the follow-up period. Patients on metformin plus DPP-4inhibitors were found to experience significantly fewer hypoglycemic events compared to the metformin plus SU 5 show the impact of the two drugs on weight and BMI. DPP-4 inhibitors produced a reduction in weight while SUs produced an increase in weight. The net difference was a decrease of 2.2 kg (95% CI 1.7 -2.7) with DPP-4 inhibitors. Change in BMI from baseline was not different between the two drugs.
Discussion
There is broad consensus that metformin should be the firstline pharmacologic therapy for patients with type 2 diabetes mellitus in whom lifestyle modification is insufficient to control hyperglycemia; however, there is still no consensus as to which drug should be added to metformin when a second therapy is necessary. SUs are a common conventional second-line therapy that stimulate insulin secretion in type 2 diabetes mellitus and reduce hyperglycemia but are associated with an increased risk of hypoglycemia. A newer drug class, the DPP-4 inhibitors, selectively inhibit the DPP-4 enzyme that degrades two major incretin hormones:
glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide [47] . They are reported to have glucose-lowering efficacy, but without the risk of hypoglycemia, when added to the treatment regimen of patients in whom metformin mono-therapy is no longer sufficient. There is also a theory that DPP-4 inhibitors could be superior to SUs with regard to the risk of cardiovascular complications [17] . To assess these potential benefits, we performed a systematic review and a meta-analysis comparing the safety and efficacy of DPP-4 inhibitors versus SUs as second-line (adjunctive) therapy when added to metformin mono-therapy for insufficiently controlled type 2 diabetic patients [8, 48] .
The results of the meta-analysis indicate that the addition of DPP-4 inhibitors to metformin mono-therapy achieves glycemic benefits similar to SUs. The reduction in HbA1c% from baseline with the addition of DPP-4 inhibitors to metformin was not significantly different than that seen with the addition of SUs to metformin mono-therapy. There were no data available to assess CVE outcomes. For other CV outcomes (arterial stiffness and blood pressure) there was no difference between the two therapies. With respect to adverse effects, metformin plus DPP-4 inhibitors was found to have a significantly lower risk of hypoglycemia compared to metformin plus SU.
The present study appears to be the first systematic review meta-analysis that compares the efficacy and safety of DPP-4 inhibitors as a group (i.e., all DPP-4 inhibitors) vs. SUs, when added to metformin mono-therapy in the treatment of patients with type 2 diabetes mellitus experiencing inadequate glycemic control. We limited the inclusion criteria to only published double-blind RCTs to obtain the highest quality evidence for addressing this clinical issue in diabetes management.
The most important limitation of this review was the high rate of missing data (>20%) in the RCTs with long-term follow-up duration (>2 years), which resulted in a considerable amount of heterogeneity in the meta-analysis results. Moreover, a range of 12-104 weeks in follow-up duration was observed for the 10 studies included in this review; which could explain the high degree of heterogeneity in the final results. Finally, there remains a need for additional long-term RCTs evaluating efficacy assessment for CVEs.
Conclusions
This systematic review shows that there is no significant difference between the efficacy of DPP-4 inhibitors and SU when used in combination with metformin mono-therapy. In contrast, the analysis showed a significant decrease in the risk of hypoglycemic events and body weight in patients using DPP-4 inhibitors. Future research should include an economic and financial analysis of DPP-4 inhibitors compared with SUs, as the medication added to metformin mono-therapy in type 2 diabetic patients with inadequate glycemic control. This would inform policy makers and clinicians by providing a comprehensive overview of the efficacy, safety and economic-financial impact of each treatment. 
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